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Abstract
Asthma frequently occurs in association with allergic rhinitis and a combined management approach has been suggested. The Control
of Allergic Rhinitis and Asthma Test (CARAT) is the first questionnaire to assess control of both diseases concurrently. However, to have
an impact on healthcare it needs to be disseminated and adopted. In this paper we discuss the dissemination of CARAT in different
countries and its possible applications in primary care. At present, the adaptation of CARAT for use in different languages and cultures
is being led by volunteer researchers and clinicians in 15 countries. Website and smartphone applications have been developed, and a
free open model of distribution was adopted to contribute to the dissemination of CARAT. Examples of dissemination activities include
distribution of leaflets and posters, educational sessions on the use of the questionnaire in the follow-up of patients, development of
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Introduction
Asthma is a heterogeneous syndrome with multiple phenotypes, the
most prevalent of which is allergic asthma in association with allergic
rhinitis.1 The World Health Organization (WHO) recognises the close
relationship between asthma and rhinitis through the Allergic
Rhinitis and its Impact on Asthma (ARIA)2 guidelines and the Global
Alliance against Chronic Respiratory Diseases (GARD) inititative.3 This
recognition has resulted in a call for a change in asthma
management and led to a combined approach for asthma and its co-
morbidities, particularly allergic rhinitis.4-7 Such an approach,
however, needs simple assessment tools that can be readily used in
clinical practice, and in primary care in particular.5,8
In 2007 a group of Portuguese allergologists, respiratory
physicians, family physicians, and paediatricians identified the need
for a questionnaire to assess asthma and allergic rhinitis control
simultaneously. The initial goal of the Control of Allergic Rhinitis and
Asthma Test (CARAT) project was to develop a questionnaire that
would meet the needs of both patients and physicians. The
questionnaire, which was designed to be self-administered by adults
with a prior diagnosis of asthma and rhinitis, was developed and
evaluated in three stages using different methodologies. We have
described these stages elsewhere.9-11
The CARAT questionnaire is composed of 10 questions that
address upper and lower airway symptoms, sleep interference,
activity limitation, and the need to increase medication over a four-
week period (see Appendix 1, available online at www.thepcrj.org).
The answers are rated on a four-point scale, with a total possible
score ranging from 0 (minimum control) to 30 (maximum control).
The properties of the questionnaire are summarised in Table 1. The
questionnaire meets nine of the 10 items on the COSMIN
(COnsensus-based Standards for the selection of health
Measurement INstruments) checklist for evaluating the
methodological quality of studies on measurement properties of
patient-reported outcomes.12 
The use of a formal methodological approach in the development
of the questionnaire and the good measurement properties observed
in the validation studies suggest that CARAT can be used in both
clinical studies and clinical practice, allowing comparison between
groups and the evaluation of individual patients over time.
clinical studies, collaborations with professional organisations and health authorities, and the inclusion of CARAT in clinical guidelines.
The adoption of innovations is an important challenge in healthcare today, and research on the degree of success of dissemination
strategies using suitable methods and metrics is much needed. We propose that CARAT can be used in a range of settings and
circumstances in primary care for clinical, research and audit purposes, within the overall aim of increasing awareness of the level of
disease control and strengthening the partnership between patients and doctors in the management of asthma and rhinitis.
© 2013 Primary Care Respiratory Society UK. All rights reserved.
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Instrument CARAT
Symptom frequency Yes
Rescue therapy use Yes
Sleep interference Yes
Activity limitation Yes
Exacerbations No
Physiologic measures No
Other No
Number of questions 10
Response format 4-point Likert scale
Scoring method Score sum 0-30
Target population; age >18 years
Time to complete <3 min
Patient report? Yes
How is it administered? Self-administered (paper, Internet, 
smart phone)
Recall period 4 weeks
Languages Portuguese (PT), French, Turkish, 
Italian, Dutch, Portuguese (BR), 
English (UK), Spanish, Greek, 
English (US), German, Swedish, 
Finnish, Slovenian, Indian
Cost to use FREE for clinical use
Internal consistency Cronbach’s alpha was 0.85 10
Reliability ICC 0.82 11
Content validity Face and content 9,10
Criterion validity Met a priori prediction for 
Hypothesis-testing correlation coefficients ranging
from 0.58 to 0.79; AUC 0.82 10
Structural validity Assessed using exploratory factor 
analysis 10
Cross-cultural validity See text
Floor and ceiling effects Not present 10
Responsiveness Significant within-patient change of 
CARAT10 scoring in clinically 
unstable patients (95% confidence 
interval [-5.08; -1.31], p=0.002). 
The Guyatt’s responsiveness index 
was 1.5411
Interpretability Clinically meaningful 11
Main advantage Simple, simultaneous evaluation of 
asthma and rhinitis in accordance 
with ARIA guidelines 
Additional information Minimal important difference
needed Sub score cut-off values clinical 
validation of electronic versions 
Table 1. CARAT characteristics and properties
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While questionnaires have been developed to assess the level of
control of asthma13,14 and more recently of rhinitis,15,16 CARAT is the
only questionnaire that concurrently assesses the control of both
disorders. This concurrent approach has previously been used to assess
disease-specific quality of life in the RHINASTHMA questionnaire.17
CARAT has recently been recognised by the ARIA group as the first
tool to help implement ARIA guidelines in primary care.3 CARAT also
meets the demand for a simple, feasible, and acceptable tool for
assessing asthma and/or rhinitis in primary care. The need for such a
tool was underlined in the recent International Primary Care
Respiratory Group (IPCRG) respiratory research needs statement18 and
in the group’s analysis of the prioritisation of these needs.19
In this paper we discuss the dissemination of CARAT in different
countries and its possible applications in primary care.
Importance of dissemination     
One of the challenges facing medicine today is the quick and
efficient translation of evidence into practice.20 Dissemination refers
to a set of planned efforts designed to make a tool, technology,
programme, or innovation more widely available.21 The use of
different approaches can help to increase awareness and use
among target populations. Moreover, new tools, technologies, and
resources need to be easily accessible and simple to use in different
settings and situations. If CARAT is to be successfully implemented
in primary care, its widespread availability is therefore crucial. 
Cross-cultural adaptations     
The ARIA group has recognised the need rapidly to test CARAT in
different languages to facilitate the implementation of this tool.3
Moreover, numerous researchers, many of whom are members of
the IPCRG, have expressed their interest in CARAT. The use of this
questionnaire in international settings, however, requires prior
translation and cross-cultural adaptation. 
To assist in this task, the CARAT team has developed a protocol
for the translation and cross-cultural adaptation of the questionnaire
based on international recommendations and best practices.22-24
Essentially, researchers interested in developing versions for their
country/language are invited to participate in the process, which is
described in detail at http://caratnetwork.org, a dedicated website
which also contains a web tool to help researchers follow the
stipulated protocol. 
The protocol has three main steps: forward translation, back
translation, and patient testing. In the forward translation step, two
people independently translate the original Portuguese
questionnaire into the target language. The translations are then
compared and an agreed version is drawn up between the
translators and the CARAT team members (first version). In the back
translation step, the text is translated back into Portuguese with the
support of the CARAT team. It is then compared with the original
and reviewed to ensure conceptual equivalence. Written feedback is
given to the researchers who produce a revised second version. The
last step is the patient test phase. Ten adult patients are given the
second version of CARAT and interviewed about the interpretation
and wording of each item. During this phase the researchers make
a note of the number of individuals interviewed, their age, the time
taken to complete the questionnaire, and any difficulties
encountered and solutions proposed. The results are reviewed and
any changes are integrated into the third and final version of the
questionnaire. 
To date, research groups from 15 countries have participated in
cross-cultural adaptations of CARAT. Many of the researchers
involved are members of the IPCRG. The current status of country-
specific versions of the questionnaire is shown in Table 2. Typically,
researchers need around 12 hrs of work to complete the cross-
cultural adaptation process and between 4 and 12 weeks are
required to produce the CARAT for a new language/
country/population. This time includes approval from a review board,
a back translation report, and feedback from the CARAT team after
the patient test phase.
CARAT can be used after completion of the cross-cultural
adaptation, but clinical validation studies would improve the
knowledge on how CARAT performs. The CARAT team has also
designed a study protocol that can be used by researchers wishing
to carry out clinical validation studies in their countries.
CARAT for children      
A CARAT questionnaire for children aged 6–12 years is currently
under development. The first version was completed in December
2011 after consensus meetings and cognitive interviews with
children and their parents, and the questionnaire is currently being
evaluated in a prospective validation study.  
CARAT-NETWORK and mCARAT       
A website and smartphone applications have been developed to
contribute to the dissemination of CARAT. In addition to providing
support for cross-cultural adaptations, the CARAT-NETWORK
(http://caratnetwork.org) provides access to the different formats
and versions of the questionnaire. Users can complete the
Country Phase Investigators
France Completed Demoly and Pereira 
Turkey Completed Yaman
Italy Completed Del Giacco
The Netherlands Completed van der Molen and Tsiligianni
Greece Completed Tsiligianni 
UK PT Garcia-Larsen
Brazil PT Gonçalves da Silva
Spain PT Román-Rodrígues and Mascarós
USA BT Yawn
Finland BT Haahtela and Pereira 
Switzerland FT Under appraisal
Germany FT
Slovenia FT
India FT
FT=forward translation, BT=back translation, PT=patient testing.
Table 2. Current status of the CARAT cross-cultural and
language adaptation process
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questionnaire online and print the results. Paper versions can also be
downloaded, and links to the smartphone applications (Android and
iOS operative systems) are available. After free online registration,
users gain access to additional tools, which include resources for
plotting and sharing the results of CARAT. 
The main features of the smartphone application (mCARAT)
have already been reported elsewhere.25 Briefly, the patient can fill in
the questionnaire, view and email the results, and synchronise with
the CARAT-NETWORK website. The Android OS version of the
application allows the user to set alarms for tasks such as taking
medications and keeping medical appointments, and also includes
features for recording symptoms, exacerbations, medication use,
and scheduled or unscheduled medical visits, as well as lung
function test results. Additionally, mCARAT allows customised
access to online educational resources about asthma and rhinitis.
The mCARAT application will shortly undergo usability and clinical
usefulness evaluation.
Dissemination experiences        
In Portugal, leaflets and posters with the questionnaire have been
distributed in primary healthcare centres, and 80 educational
sessions on the use of the questionnaire in the follow-up of patients
with asthma and rhinitis have been held with the participation of
over 1200 physicians, nurses, and pharmacists. Furthermore, the
Portuguese Government recommended CARAT for the follow-up of
patients in the 2011 asthma guidelines. 
In the Netherlands the cross-cultural adaptation has been
completed and further research is underway to assess asthma and
rhinitis control in the Dutch population during the allergy season. 
In the UK, the standard operational procedure for translation of
CARAT into English has been completed and the project is currently
being reviewed for ethical approval at Imperial College London.
A Spanish version has also been developed for use in Spain and
Spanish-speaking countries. The questionnaire is now awaiting
clinical validation. 
In Italy, the cross-cultural and language adaptation process has
been successfully completed, and preparations are being made in
collaboration with the Italian General Practitioners’ Medical Society
for a preliminary evaluation of the use of CARAT in primary care.
The Greek version of the questionnaire has also been produced,
with results showing that it is easy to complete for both clinicians
and patients. Further dissemination is anticipated within the Greek
Association of General Practitioners (ELEGEIA) and the Clinic of
Social and Family Medicine of the University of Crete. 
The Brazilian version of CARAT is under clinical validation.
Unpublished preliminary data indicate that it may increase
compliance  with treatment, and understanding of disease, among
Brazilian patients.
Use case scenarios in primary care  
Currently, CARAT can be used to assess disease control in adults
with a prior diagnosis of asthma and rhinitis in a range of settings
and circumstances (Figure 1). These include follow-up consultations
(general practice or allergy/asthma outpatient clinics), nurse
consultations, pharmacy services, lung function laboratories, and
patient self-monitoring. 
The information generated by the questionnaire has three broad
applications: (1) by providing an objective measure of disease
control, it can be used to support clinical decision-making and
increase patient awareness of their level of asthma/rhinitis control;
(2) it can be used for patient-reported outcome assessments in
asthma/rhinitis research; and (3) it can be used to assess and
improve the quality of asthma/rhinitis care and may have a role in
the benchmarking of healthcare quality. 
By increasing patient awareness of their level of asthma/rhinitis
control and enhancing patient empowerment, CARAT has the
potential to contribute to strengthening the much needed
partnership between patients and doctors. In this regard, we believe
that the involvement of patient organisations in the dissemination of
the questionnaire is to be encouraged. The fact that the questionnaire
is freely and easily available in various formats should encourage its
use among patients and help to engage them in their own care.
Questions for the future   
The dissemination and adoption of any healthcare innovation is a long
and difficult process, with uncertain outcomes. Evaluation of
dissemination strategies should thus become a standard component
of this process, but equally important are suitable methods and
metrics to evaluate the effectiveness of innovations in clinical practice.  
Future research in primary care settings needs to investigate
whether the combined assessment of rhinitis and asthma control
during routine clinical visits reduces the risk of exacerbations,
emergency room attendances, and hospital admissions and
improves patients’ quality of life. It also needs to assess how – and
how often – CARAT results change clinical decisions made by
physicians in the routine assessment of asthma and how it changes
the patient’s understanding and adherence to the physician’s
therapeutic decision.
Moreover, to ensure that CARAT meets all the quality criteria of
COSMIN, analysis of large longitudinal datasets is needed to
establish the minimal clinically important difference of the
Figure 1.  CARAT use case scenarios
*Under development;  #Under evaluation
Adults
Children#
Follow-up
consultations
Pharmacy services#
Home/daily life*
Paper questionaire
Caratnetwork.org#
m.CARAT#
Clinical decision-
making support
Audit*
Research
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questionnaire and the definitive cut-off values for the CARAT overall
score and subscores. It is within the scope of this research group to
provide these answers in the near future. 
Conclusions 
CARAT is the first questionnaire to assess control of asthma and
allergic rhinitis concurrently. However, to have an impact on
healthcare it needs to be disseminated and adopted. The
dissemination approaches used were: (1) widespread availability
(cross-cultural adaptations, print, web, and mobile versions); (2) a
free open model of distribution; (3) user support through a
dedicated website; (4) clinical educational sessions; and (5) dialogue
with health authorities and integration into clinical guidelines.
At present the adaptation of CARAT for use in different
languages and cultures is being led by volunteer researchers and
clinicians in 15 countries. Studying the degree of success of
dissemination strategies using suitable methods and metrics is much
needed as adoption of innovations is an important challenge in
healthcare today.
We propose that CARAT be used in primary care for clinical,
research, and audit purposes, within the overall aim of
strengthening the partnership between patients and doctors in the
management of asthma and rhinitis. 
Handling editor Mike Thomas
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